{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T14:39:03Z","timestamp":1776436743665,"version":"3.51.2"},"reference-count":48,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bioengineering"],"abstract":"<jats:p>Necrotizing soft tissue infections (NSTIs) are serious and aggressive infections which can result in significant morbidity and mortality. Both prompt surgical intervention and early antibiotics can decrease patient mortality. Based on microbiology, NSTIs can be categorized into four different types. Type I is polymicrobial, caused by a mix of both anaerobic and aerobic bacteria. Type II is monomicrobial, usually caused by either Streptococcus or Staphylococcus. Type III infections are caused by Gram-negative bacteria, often marine-related organisms, such as Vibrio. Lastly, Type IV infections are caused by fungi, and they are often associated with trauma. Despite the possibility of all these different pathogens in NSTI, early therapy often consists of a broad Gram-positive antimicrobial such as linezolid or vancomycin, and a broad Gram-negative agent such as piperacillin\/tazobactam. Multiple factors including patient comorbidities, environmental exposures, and clinical presentation must also be considered when choosing antimicrobial agents and dosing. Adjunct medical therapies such as intravenous immunoglobulin (IVIG) and the antibiotics clindamycin and linezolid that are aimed at toxin suppression may be utilized to improve outcomes. Microbiological data are critical for optimizing the antimicrobial regimen.<\/jats:p>","DOI":"10.3390\/bioengineering12070691","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T12:05:40Z","timestamp":1750766740000},"page":"691","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Optimizing Antibiotic Choice, Administration, and Duration in NSTI Treatment"],"prefix":"10.3390","volume":"12","author":[{"given":"Devorah","family":"Howell","sequence":"first","affiliation":[{"name":"University of Maryland Medical Center, Division of Infectious Diseases, R. Adams Cowley Shock Trauma Center, Baltimore, MD 21201, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachael","family":"Edgin","sequence":"additional","affiliation":[{"name":"University of Maryland Medical Center, Division of Infectious Diseases, R. Adams Cowley Shock Trauma Center, Baltimore, MD 21201, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aliya","family":"Rehman","sequence":"additional","affiliation":[{"name":"University of Maryland School of Medicine, Department of Medicine, Division of Infectious Diseases, R. Adams Cowley Shock Trauma Center, Baltimore, MD 21201, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0146-1736","authenticated-orcid":false,"given":"Ronald","family":"Rabinowitz","sequence":"additional","affiliation":[{"name":"University of Maryland School of Medicine, Department of Medicine, Division of Infectious Diseases, R. Adams Cowley Shock Trauma Center, Baltimore, MD 21201, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1056\/NEJMra1600673","article-title":"Necrotizing Soft-Tissue Infections","volume":"377","author":"Stevens","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/cid\/ciu444","article-title":"Executive Summary: Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America","volume":"59","author":"Stevens","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.idc.2017.05.011","article-title":"Evaluation and Management of Necrotizing Soft Tissue Infections","volume":"31","author":"Bonne","year":"2017","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e01508","DOI":"10.1016\/j.idcr.2022.e01508","article-title":"Necrotizing fasciitis and gas gangrene due to Aeromonas hydrophila in an immunocompetent host: A rare entity","volume":"28","author":"Mohanty","year":"2022","journal-title":"IDCases"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1128\/jcm.33.9.2382-2387.1995","article-title":"Clinical and microbiological features of necrotizing fasciitis","volume":"33","author":"Brook","year":"1995","journal-title":"J. Clin. Microbiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1378\/chest.110.1.219","article-title":"Necrotizing Fasciitis","volume":"110","author":"Green","year":"1996","journal-title":"Chest"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"764","DOI":"10.7326\/M19-0085","article-title":"Fournier Gangrene Associated With Sodium\u2013Glucose Cotransporter-2 Inhibitors","volume":"170","author":"Chamberlain","year":"2019","journal-title":"Ann. Intern. Med."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Urbina, T., Razazi, K., Ourghanlian, C., Woerther, P.-L., Chosidow, O., Lepeule, R., and de Prost, N. (2021). Antibiotics in Necrotizing Soft Tissue Infections. Antibiotics, 10.","DOI":"10.3390\/antibiotics10091104"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"dlad157","DOI":"10.1093\/jacamr\/dlad157","article-title":"Association of piperacillin and vancomycin exposure on acute kidney injury during combination therapy","volume":"6","author":"Venugopalan","year":"2023","journal-title":"JAC-Antimicrob. Resist."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e0088621","DOI":"10.1128\/AAC.00886-21","article-title":"Acute Kidney Injury Associated with Area under the Curve versus Trough Monitoring of Vancomycin in Obese Patients","volume":"66","author":"Wallace","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1089\/sur.2022.294","article-title":"Defining the Optimal Antibiotic Duration in Necrotizing Skin and Soft Tissue Infections: Clinical Experience from a Quaternary Referral Center","volume":"24","author":"Horn","year":"2023","journal-title":"Surg. Infect."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Blackman, A.L., Jarugula, P., Nicolau, D.P., Chui, S.H., Joshi, M., Heil, E.L., and Gopalakrishnan, M. (2021). Evaluation of Linezolid Pharmacokinetics in Critically Ill Obese Patients with Severe Skin and Soft Tissue Infections. Antimicrob. Agents Chemother., 65.","DOI":"10.1128\/AAC.01619-20"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Simon, P., Busse, D., Petroff, D., Dorn, C., Ehmann, L., Hochst\u00e4dt, S., Girrbach, F., Dietrich, A., Zeitlinger, M., and Kees, F. (2020). Linezolid Concentrations in Plasma and Subcutaneous Tissue are Reduced in Obese Patients, Resulting in a Higher Risk of Underdosing in Critically Ill Patients: A Controlled Clinical Pharmacokinetic Study. J. Clin. Med., 9.","DOI":"10.3390\/jcm9041067"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1093\/jac\/dky500","article-title":"Pharmacokinetic evaluation of linezolid administered intravenously in obese patients with pneumonia","volume":"74","author":"Xie","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1093\/cid\/cis856","article-title":"Continuous Infusion of Beta-Lactam Antibiotics in Severe Sepsis: A Multicenter Double-Blind, Randomized Controlled Trial","volume":"56","author":"Dulhunty","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S1473-3099(17)30615-1","article-title":"Prolonged versus short-term intravenous infusion of antipseudomonal \u03b2-lactams for patients with sepsis: A systematic review and meta-analysis of randomised trials","volume":"18","author":"Vardakas","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s00134-015-4188-0","article-title":"Beta-Lactam Infusion in Severe Sepsis (BLISS): A prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis","volume":"42","author":"Sulaiman","year":"2016","journal-title":"Intensiv. Care Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/TA.0000000000001562","article-title":"Less is more? Antibiotic duration and outcomes in Fournier\u2019s gangrene","volume":"83","author":"Lauerman","year":"2017","journal-title":"J. Trauma Acute Care Surg."},{"key":"ref_19","unstructured":"Narsana, M.M., Schrank, G.M.M., Leuthy, P.P., and Rabinowitz, R.M. (2019). Necrotizing Soft Tissue Infections Involving Actinomyces Species Identified by the Matrix-Assisted Laser Desorption Ionzation Time-of-Flight (MALDI-TOF), New But Not Improved."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/QCO.0000000000000431","article-title":"Treatment of severe skin and soft tissue infections: A review","volume":"31","author":"Burnham","year":"2018","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1093\/cid\/ciw871","article-title":"Impact of Intravenous Immunoglobulin on Survival in Necrotizing Fasciitis With Vasopressor-Dependent Shock: A Propensity Score\u2013Matched Analysis From 130 US Hospitals","volume":"64","author":"Kadri","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_22","unstructured":"Centers for Disease Control and Prevention (2025, April 21). Group A Strep Disease Surveillance and Trends, Available online: https:\/\/www.cdc.gov\/group-a-strep\/php\/surveillance\/."},{"key":"ref_23","unstructured":"(2025, April 22). Center for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs) Report\u2014Emerging Infections Program Network\u2014Group A Streptococcus, 2022, Available online: https:\/\/www.cdc.gov\/abcs\/downloads\/GAS_Surveillance_Report_2022.pdf."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1001\/jama.2025.0910","article-title":"Invasive Group A Streptococcal Infections in 10 US States","volume":"333","author":"Gregory","year":"2025","journal-title":"JAMA"},{"key":"ref_25","unstructured":"World Health Organization (2022). Increased Incidence of Scarlet Fever and Invasive Group A Streptococcus Infection\u2014Multi-Country."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1128\/IAI.01291-06","article-title":"Determination of the Relationship between Group A Streptococcal Genome Content, M Type, and Toxic Shock Syndrome by a Mixed Genome Microarray","volume":"75","author":"Vlaminckx","year":"2007","journal-title":"Infect. Immun."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1128\/CMR.00101-13","article-title":"Disease Manifestations and Pathogenic Mechanisms of Group A Streptococcus","volume":"27","author":"Walker","year":"2014","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_28","first-page":"e33146","article-title":"Group A Streptococcus Infections: Their Mechanisms, Epidemiology, and Current Scope of Vaccines","volume":"14","author":"Iyer","year":"2022","journal-title":"Cureus"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/cid\/ciu304","article-title":"Effectiveness of Clindamycin and Intravenous Immunoglobulin, and Risk of Disease in Contacts, in Invasive Group A Streptococcal Infections","volume":"59","author":"Carapetis","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S1473-3099(20)30523-5","article-title":"Effectiveness of adjunctive clindamycin in \u03b2-lactam antibiotic-treated patients with invasive \u03b2-haemolytic streptococcal infections in US hospitals: A retrospective multicentre cohort study","volume":"21","author":"Babiker","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1128\/AAC.47.5.1752-1755.2003","article-title":"Influences of Linezolid, Penicillin, and Clindamycin, Alone and in Combination, on Streptococcal Pyrogenic Exotoxin A Release","volume":"47","author":"Coyle","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S1473-3099(24)00507-3","article-title":"Adjunctive linezolid versus clindamycin for toxin inhibition in \u03b2-lactam-treated patients with invasive group A streptococcal infections in 195 US hospitals from 2016 to 2021: A retrospective cohort study with target trial emulation","volume":"25","author":"Babiker","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"ofad588","DOI":"10.1093\/ofid\/ofad588","article-title":"Comparison of Adjuvant Clindamycin vs Linezolid for Severe Invasive Group A Streptococcus Skin and Soft Tissue Infections","volume":"10","author":"Heil","year":"2023","journal-title":"Open Forum Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1473-3099(09)70066-0","article-title":"Gram-positive toxic shock syndromes","volume":"9","author":"Lappin","year":"2009","journal-title":"Lancet Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1093\/cid\/ciaa022","article-title":"Correlation Between Immunoglobulin Dose Administered and Plasma Neutralization of Streptococcal Superantigens in Patients With Necrotizing Soft Tissue Infections","volume":"71","author":"Bergsten","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"S106","DOI":"10.1111\/j.1444-0903.2005.00984.x","article-title":"Recognition and management of Staphylococcus aureus toxin-mediated disease","volume":"35","author":"Murray","year":"2005","journal-title":"Intern. Med. J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1093\/cid\/ciu449","article-title":"Clinical Efficacy of Polyspecific Intravenous Immunoglobulin Therapy in Patients With Streptococcal Toxic Shock Syndrome: A Comparative Observational Study","volume":"59","author":"Linner","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1086\/376630","article-title":"Intravenous Immunoglobulin G Therapy in Streptococcal Toxic Shock Syndrome: A European Randomized, Double-Blind, Placebo-Controlled Trial","volume":"37","author":"Darenberg","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1007\/s00134-017-4786-0","article-title":"Immunoglobulin G for patients with necrotising soft tissue infection (INSTINCT): A randomised, blinded, placebo-controlled trial","volume":"43","author":"Madsen","year":"2017","journal-title":"Intensiv. Care Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1086\/606048","article-title":"Intravenous Immunoglobulin in Children with Streptococcal Toxic Shock Syndrome","volume":"49","author":"Shah","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1093\/cid\/ciy401","article-title":"Polyspecific Intravenous Immunoglobulin in Clindamycin-treated Patients With Streptococcal Toxic Shock Syndrome: A Systematic Review and Meta-analysis","volume":"67","author":"Parks","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s40138-018-0166-5","article-title":"Hyperbaric Oxygen Therapy and Utilization in Infectious Disease","volume":"6","author":"Bennett","year":"2018","journal-title":"Curr. Emerg. Hosp. Med. Rep."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e2627","DOI":"10.1097\/MD.0000000000002627","article-title":"Distribution of Fatal Vibrio Vulnificus Necrotizing Skin and Soft-Tissue Infections","volume":"95","author":"Huang","year":"2016","journal-title":"Medicine"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1007\/s10096-019-03629-5","article-title":"Epidemiology, pathogenetic mechanism, clinical characteristics, and treatment of Vibrio vulnificus infection: A case report and literature review","volume":"38","author":"Leng","year":"2019","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Grilo, M.L., Pereira, A., Sousa-Santos, C., Robalo, J.I., and Oliveira, M. (2021). Climatic Alterations Influence Bacterial Growth, Biofilm Production and Antimicrobial Resistance Profiles in Aeromonas spp.. Antibiotics, 10.","DOI":"10.3390\/antibiotics10081008"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Wong, K.C., Brown, A.M., Luscombe, G.M., Wong, S.J., and Mendis, K. (2015). Antibiotic use for Vibrio infections: Important insights from surveillance data. BMC Infect. Dis., 15.","DOI":"10.1186\/s12879-015-0959-z"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1128\/AAC.05387-11","article-title":"Antimicrobial Susceptibilities of Aeromonas Strains Isolated from Clinical and Environmental Sources to 26 Antimicrobial Agents","volume":"56","author":"Inglis","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4037\/ajcc2005.14.2.109","article-title":"Adjunctive use of plasmapheresis and intravenous immunoglobulin therapy in sepsis: A case report","volume":"14","author":"Kyles","year":"2005","journal-title":"Am. J. Crit. Care"}],"container-title":["Bioengineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2306-5354\/12\/7\/691\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:58:00Z","timestamp":1760032680000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2306-5354\/12\/7\/691"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,24]]},"references-count":48,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["bioengineering12070691"],"URL":"https:\/\/doi.org\/10.3390\/bioengineering12070691","relation":{},"ISSN":["2306-5354"],"issn-type":[{"value":"2306-5354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,24]]}}}